NUVL
Nuvalent, Inc.
NASDAQ · Healthcare · Biotechnology · US
$123.96
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 316.2M | 307.0M | 217.8M | 113.2M | 63.7M |
| SG&A Expense | 122.7M | 107.3M | 62.6M | 36.2M | 22.4M |
| General & Admin Expense | 122.7M | 107.3M | 62.6M | 36.2M | 22.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 438.9M | 414.3M | 280.4M | 149.5M | 86.1M |
| Cost and Expenses | 438.9M | 414.3M | 280.4M | 149.5M | 86.1M |
| Operating Income (EBIT) | (438.9M) | (414.3M) | (280.4M) | (149.5M) | (86.1M) |
| Non-Operating | |||||
| Interest Income | 42.1M | 44.7M | 38.3M | 23.3M | — |
| Interest Expense | 12.9M | — | — | 23.3M | — |
| Net Interest Income | 29.2M | 44.7M | 38.3M | — | — |
| Other Non-Op Income/Expense | (10.6M) | (10.5M) | 20.4M | 23.3M | 4.3M |
| Non-Operating Income (excl Interest) | (2.3M) | 10.5M | (20.4M) | (23.3M) | (4.3M) |
| EBT (Pre-Tax Income) | (449.5M) | (424.8M) | (260.0M) | (126.2M) | (81.9M) |
| Income Tax Expense | 596.0K | 585.0K | 764.0K | — | — |
| Bottom Line | |||||
| Net Income | (450.1M) | (425.4M) | (260.8M) | (126.2M) | (81.9M) |
| Earnings from Cont. Ops | (450.1M) | (425.4M) | (260.8M) | (126.2M) | (81.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (450.1M) | (425.4M) | (260.8M) | (126.2M) | (81.9M) |
| Per Share | |||||
| Basic EPS | ($6.06) | ($5.85) | ($3.93) | ($2.17) | ($1.65) |
| Diluted EPS | ($6.06) | ($5.85) | ($3.93) | ($2.17) | ($1.65) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 78.7M | 72.7M | 66.4M | 58.2M | 49.7M |
| Diluted Shares Outstanding | 78.7M | 72.7M | 66.4M | 58.2M | 49.7M |
| Profitability Metrics | |||||
| EBITDA | (334.4M) | (10.5M) | 20.4M | (126.2M) | (81.9M) |
| D&A | 102.2M | 414.3M | 280.4M | — | — |
| EBIT | (436.6M) | (424.8M) | (260.0M) | (126.2M) | (81.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026